Stem Cells in Treating Severe Autoimmune Diseases: A 15-Year Remission Report. Two patients with severe neuromyelitis optica have stayed relapse-free for over 15 years after stem cell transplant. Here is what the 2026 report shows, an
A June 2026 case report in Med describes two patients with treatment-resistant neuromyelitis optica spectrum disorder who remained relapse-free for 15 and 16 years after allogeneic haematopoietic stem cell transplantation. The procedure rebuilds the immune system rather than modulating it, which differs from mesenchymal cell approaches. As a two-patient report it does not establish how often such remission occurs, and larger controlled studies remain necessary.
A June 2026 report has renewed discussion about how far cell-based approaches can go in severe autoimmune disease. Two patients with neuromyelitis optica spectrum disorder (NMOSD), a rare condition in which antibodies attack the optic nerves and spinal cord, have remained relapse-free for more than 15 years after receiving allogeneic haematopoietic stem cell transplants. The case report was published in Med, and both patients had disease that no longer responded to standard immunosuppression.
The result is a two-person case report rather than a trial, so it does not establish a general treatment. What it does provide is an unusually long window on what happens after the immune system is rebuilt from donor stem cells.
| Element | What Was Reported |
|---|---|
| Condition | Neuromyelitis optica spectrum disorder, AQP4-IgG antibody positive |
| Patients | Two, one man and one woman, with treatment-resistant disease |
| Procedure | Allogeneic haematopoietic stem cell transplantation from donor cells |
| Follow-up | Relapse-free at 15 and 16 years after transplant |
| Findings | No clinical relapses, with imaging and antibody status followed long-term |
| Publication | Case report in Med, June 2026 |
Both patients had exhausted conventional options before transplant. Long-term imaging of the optic nerves and spinal cord was reviewed alongside clinical status, which is why the report attracted attention: sustained remission in NMOSD over this timescale has not previously been documented after this procedure.
Two very different cell types are often discussed under the same heading, and conflating them causes most of the confusion around stem cells in treating severe autoimmune diseases.
The distinction matters clinically. Haematopoietic transplantation is an intensive hospital procedure with conditioning chemotherapy and real transplant-related risk. MSC-based approaches sit in a different category of intervention and are discussed in how cell therapy may support autoimmune conditions.
Severe autoimmune conditions share a feature that makes the reset concept plausible: the problem is written into the immune system itself rather than into the target tissue.
The underlying mechanisms are covered in what an autoimmune disease is and in the link between autoimmune disease and chronic inflammation.
Interpreting this report accurately requires holding two things at once.
Durable remission raises the question of how immune tolerance is re-established rather than merely suppressed. Regulatory T cell populations are central to that question, and they are the mechanism most often invoked when researchers describe tolerance being restored instead of dampened. That relationship is examined in how stem cells interact with regulatory T cells.
For someone whose autoimmune condition keeps relapsing, this report is a reason for interest and not a route to treatment.
Considerations for difficult-to-control disease more broadly are set out in cell therapy for difficult autoimmune conditions.
Two patients with severe NMOSD remaining relapse-free beyond 15 years after allogeneic stem cell transplantation is a meaningful long-term observation, not a demonstration that the approach works broadly. It strengthens the case for studying immune reset in refractory autoimmune disease, while leaving the questions of who benefits, how often, and at what risk to larger controlled research.
This article is for general informational and educational purposes only and is not a substitute for personalized medical advice. Always consult a qualified healthcare professional before considering stem cell therapy.